Oncolytics Biotech (ONCY)
Develops pelareorep, a double-stranded RNA immunotherapy for gastrointestinal tumors.
Something off on this page? Send us feedback.
Develops pelareorep, a double-stranded RNA immunotherapy being advanced as a platform for gastrointestinal tumors. It is a clinical-stage business centered on a single lead candidate, with no approved commercial product described in the reviewed materials.
Develops pelareorep, a double-stranded RNA immunotherapeutic agent that traces back to the REOLYSIN program. The development-stage business is centered on that single candidate, which is being advanced as a platform immunotherapy for gastrointestinal tumors.
Pancreatic and colorectal programs have FDA Fast Track designations. The reviewed materials do not describe an approved commercial product, and the company keeps its headquarters in San Diego while retaining a Calgary office.
Clinical development and regulatory milestones are the central operating activities. Continued operations depend on additional financing; existing cash was reported as sufficient for near-term milestones but not for a full year of planned operations from the filing date.
Company facts
No analyst consensus on record.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $4.1M · Total debt $448.0K · Total assets $7.7M · Shareholders' equity −$6.2M
- Revenue
- $0
- Operating income
- −$9.4M
- Net income
- −$9.4M
Reported in CAD, converted at the latest exchange rate
No dividends on record.
| Institutions | 3.96% | 3.98M ADS | |
|---|---|---|---|
| 78 holders · as of Jun 30, 2026 | |||
| Other | 96.04% | 96.38M ADS | |
| remainder | |||
100.36M ADS as of Sep 14, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count is from the company's Dec 2024 annual report; nothing newer is on file here.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Anson Funds Management LPInstitution | 7.62% | 7.65M | filed Nov 14, 2025 |
Marshall Wace, LLPInstitution | 0.74% | 745,350 ADS | as of Jun 30, 2026 |
XTX Topco LtdInstitution | 0.26% | 260,903 ADS | as of Jun 30, 2026 |
Seeds Investor LLCInstitution | 0.26% | 258,306 ADS | as of Jun 30, 2026 |
International Assets Investment Management, LLCInstitution | 0.20% | 201,260 ADS | as of Jun 30, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Mar 12, 2026 | Jared Kelly | director, officer: Chief Executive Officer | +5,050 | $0.9600 |
| Mar 11, 2026 | James T. Parsons | director | +10,000 | $1.03 |
| Feb 12, 2026 | Patricia S. Andrews | director | +35,400 | $0.8557 |
| Feb 11, 2026 | Andrew Aromando | officer: Chief Business Officer | +29,600 | $0.8587 |
| Feb 11, 2026 | Bernd R. Seizinger | director | +60,000 | $0.8265 |
- Theriva Biologics
Oncolytic adenovirus program in metastatic pancreatic cancer
- Agenus
MSS metastatic colorectal immunotherapy program
- Replimune Group
Oncolytic-immunotherapy platform with liver and biliary trials
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Oncolytics Biotech | $0.6857 | −3.87% | $71.6M | — | — | — | — |
| Theriva Biologics | $0.2330 | +0.95% | $10.6M | — | — | 35.3 | +94.8% |
| Agenus | $8.48 | −2.53% | $362.3M | 3.3 | — | 2.7 | +34.3% |
| Replimune Group | $12.84 | −4.71% | $1.13B | — | — | — | — |
| Median | 3.3 | — | 19.0 | +64.6% |